Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Allergic Contact Dermatitis
NCT05498467Phase 3Completed
- Sponsor
- Herlev & Gentofte Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2023
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of anakinra in allergic contact dermatitis (ACD), sponsored by Herlev & Gentofte Hospital. Primary endpoint: Clinical Reaction ICDRG Score at 2 months. Started Oct 2022; status: completed.
02
Drugs
anakinra
03
Conditions
allergic contact dermatitis (ACD)
Beyond the preview
Go deeper on NCT05498467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498467.